BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq:CELG) today announced more mature data from clinical studies of REVLIMID (lenalidomide) in newly-diagnosed multiple myeloma were presented at a joint symposium of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) on Sunday, Dec. 7. The results from the ECOG E4A03 study of REVLIMID plus low-dose dexamethasone (Rd) versus REVLIMID plus a standard dose of dexamethasone (RD) in newly diagnosed multiple myeloma patients detailed some of the highest three-year overall survival rates ever reported in the intent to treat population. These results showed a three-year survival rate of 75 percent in the RD arm of the study and 74 percent in the Rd arm.
